Κατεύθυνση Αρτηριακή Υπέρταση και Συνοδά Καρδιαγγειακά-Νεφρικά Νοσήματα
Library of the School of Health Sciences

2020-10-15

2020

Siafi Eirini-Charikleia

Τσιούφης Κωνσταντίνος: Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Τούσουλης Δημήτριος: Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Αγγέλη Κωνσταντίνα : Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ

Μη αλκοολική λιπώδης διήθηση του ήπατος και υπέρταση (ανασκόπηση)

Greek

Non-alcoholic fatty liver disease and hypertension (review)

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. NAFLD represents a spectrum of diseases ranging from hepatocellular steatosis through steatohepatitis to cirrhosis and hepatocellular carcinoma (HCC). It affects one third of the general population and risk factors are arterial hypertension, obesity, diabetes mellitus, dyslipidemia, and lack of physical activity. The diagnosis of NAFLD requires the presence of hepatic steatosis, the absence of alcohol abuse and other secondary causes of fat deposition in the liver. NAFLD is associated with increased risk of cardiovascular disease, which is the leading cause of death, followed by cirrhosis and HCC.
Many studies have tried to investigate the association between NAFLD and hypertension. The close relationship between those two diseases has been demonstrated in recent years. Insulin resistance, renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system could be the link between NAFLD and hypertension. According to recent studies, patients with NAFLD should receive effective blood pressure control by specific antihypertensive treatment ,such as RAAS inhibitors and mainly angiotensin receptor blockers, that may delay the progression of NAFLD.

Health Sciences

Hypertension, Blood pressure, Antihypertensive treatment, Non-alcoholic fatty liver disease, Fatty liver, Steatohepatitis

No

0

No

122

68

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/2924616